Thalidomide is a piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.

P005091 is a selective and potent inhibitor of ubiquitin-specific protease 7 (USP7).

PRT 4165 is a Bmi1/Ring1A inhibitor, also inhibits PRC1-mediated H2A ubiquitylation in vivo and in vitro.

DBeQ is a selective, potent, reversible, and ATP-competitive p97 inhibitor.

Necrostatin 2 racemate inhibits necroptosis induced by tumor necrosis factor alpha (TNF-a) with EC50 of 0.21 μM.

MG132 is a potent cell-permeable proteasome and calpain inhibitor.

BAY 11-7082 is a NF-κB inhibitor.

b-AP15 is a deubiquitinases inhibitor for 19S proteasomes activity of Ub-AMC cleavage with IC50 of 2.1 μM.